Plain-English translation of NCT06249945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether empagliflozin—a medication originally designed to help control blood sugar in people with diabetes—can safely and effectively treat a specific type of heart failure in patients who are on kidney dialysis. Heart failure with preserved ejection fraction (a condition where the heart doesn't relax properly) is common in people with advanced kidney disease, but treatment options are very limited. Early research suggests this medication might help, even in patients whose kidneys no longer work.
People with advanced kidney disease often develop a type of heart failure that is difficult to treat, and most heart failure medications have never been properly tested in dialysis patients. This trial exists to find out whether this medication can safely help this overlooked group of patients.
You likely qualify if…
You likely don't qualify if…
You would take either the study medication or a placebo (a pill with no active ingredient) once a day for 6 months. You would visit the research clinic regularly for check-ups, blood tests, and heart monitoring to see how you're doing. Half of the participants will receive the actual medication, and half will receive placebo—neither you nor the researchers will know which one you're taking until the trial ends.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Taiwan